Cancer News and Research

Latest Cancer News and Research

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA.

30 Jul 2010

Geron second-quarter net loss decreases to $17.0 million

Geron Corporation today reported financial results for the three and six months ended June 30, 2010.

30 Jul 2010

BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

BioCurex Inc. today announced that the International Society of Oncology and Biomarkers Congress Scientific Committee has accepted BioCurex's presentation on the RECAF blood test potential to monitor cancer recurrence and treatment. The meeting will be held Sept. 3-8, 2010 in Munich, Germany and is broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics.

30 Jul 2010

Prostate basal cell can spawn tumors in prostate gland: Research

A type of prostate cell that has been largely ignored by cancer researchers can, in fact, trigger malignant prostate cancer, according to new studies by Howard Hughes Medical Institute (HHMI) scientists and their colleagues.

30 Jul 2010

TNF blockers may increase the risk of malignancy in children

The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation.

29 Jul 2010

NeoGenomics second-quarter 2010 revenue increases 14% to $8.5 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2010.

29 Jul 2010

Isis Pharmaceuticals receives $5M payment from GSK for dug development

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.

29 Jul 2010

BCBSNC receives CEO Cancer Gold Standard certification

Blue Cross and Blue Shield of North Carolina has received CEO Cancer Gold Standard accreditation, recognizing the organization's commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

29 Jul 2010

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene Corporation announced non-GAAP net income of $323.3 million, or non-GAAP diluted earnings per share of $0.69 for the quarter ended June 30, 2010. Non-GAAP net income for the second quarter of 2009 was $216.0 million or non-GAAP diluted earnings per share of $0.46.

29 Jul 2010

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

Cord Blood America announces highlights for 6-month period ended June 30, 2010

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced highlights for the six-month period ended June 30, 2010. The Company believes the period was the most significant and eventful in its history.

29 Jul 2010

Senate Commission presents 2010 list of MAK and BAT values containing new data on 61 substances

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.

29 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Researchers examine why some obese people become diabetic while others do not

Why some obese people go on to become diabetic while others do not. It is common to find obese people - even morbidly obese people - who are healthier than their condition would normally allow.

29 Jul 2010

Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials

Bionovo, Inc. announced today that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba.

29 Jul 2010

Two middle school students join scientists to research on key bacterial enzyme

Grown-ups aren't the only ones making exciting scientific discoveries these days. Two middle school students from Wisconsin joined a team of scientists who are reporting the first glimpse of the innermost structure of a key bacterial enzyme. It helps activate certain antibiotics and anti-cancer agents so that those substances do their job. Their study appears in ACS' weekly journal Biochemistry.

29 Jul 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

ACS CAN report finds nearly half of all states falling short on legislative solutions to prevent, fight cancer

Nearly half of all states are falling short on legislative solutions to prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN). However, despite budget crises in several states, some state lawmakers still made positive progress in the fight against a disease that will kill an estimated 569,000 people in the United States this year.

29 Jul 2010

Cancer News and Research

Latest Cancer News and Research

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Geron second-quarter net loss decreases to $17.0 million

BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

Prostate basal cell can spawn tumors in prostate gland: Research

TNF blockers may increase the risk of malignancy in children

NeoGenomics second-quarter 2010 revenue increases 14% to $8.5 million

Isis Pharmaceuticals receives $5M payment from GSK for dug development

BCBSNC receives CEO Cancer Gold Standard certification

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Cord Blood America announces highlights for 6-month period ended June 30, 2010

Senate Commission presents 2010 list of MAK and BAT values containing new data on 61 substances

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

AVEO second-quarter total revenues increase to $15.6 million

Researchers examine why some obese people become diabetic while others do not

Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials

Two middle school students join scientists to research on key bacterial enzyme

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

ACS CAN report finds nearly half of all states falling short on legislative solutions to prevent, fight cancer

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in